GMAB: Genmab AS Price-to-Revenue Multiple

Symbol and logo of brand Genmab AS (GMAB)

Genmab A/S generates revenue by licensing advanced antibodies and collecting royalties from pharmaceutical behemoths. The price-to-sales ratio reflects the market reaction to this business model. The company relies on unique oncology patents, while flawless temperature-controlled delivery ensures drug integrity. Meanwhile, the 7.40 metric serves as the target level for assessing current market capitalization.

GMAB Genmab Corp Market Cap to Revenue (07/04/2022 - 11/13/2026)

Analytical breakdowns for Genmab US (GMAB)

- share price and consensus valuation forecast:
Price Performance Chart genmab.com|GMAB - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Genmab US|GMAB - Enterprise Value
- book capitalization data:
Net Asset Value per Share Genmab|GMAB - Company Net Assets|Market Cap to Book Value Multiple genmab.com|GMAB - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Genmab A/S|GMAB - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Genmab Corp|GMAB - Company Total Debt|Debt to Net Assets Ratio Genmab US|GMAB - Company Long-Term Liabilities|Amount of Current Liabilities Genmab|Intermediate Coverage Ratio genmab.com
- earnings and multiples data:
GMAB - Net Profit|Expected Net Profit Genmab A/S|GMAB - Price to Earnings Ratio|Future Price to Earnings Multiple Genmab AS|GMAB - PEG Multiple|EV/EBITDA Multiple Genmab US|GMAB - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Genmab|GMAB - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months genmab.com|GMAB - Earnings growth in current year|Net earnings per one share growth forecast for next year Genmab A/S
- sales revenue and business income indicators:
GMAB - Revenue and Sales Volume|Company Expected Sales Volume genmab.com|GMAB - Price-to-Revenue Ratio|Market Cap to Projected Revenue Genmab US
Summary company analytics:genmab.com, GMAB
Mass-produced product of genmab.com

To minimize risks, it is essential for an investor to evaluate the revenue premium the market is willing to pay for every dollar of operating income generated by Genmab A/S. Analyzing the historical P/S ratio can confirm the business's resilience: a powerful oncology patent portfolio and stable royalties from pharma behemoths create a defensive barrier, turning the current multiple into an indicator of either fundamental undervaluation or the asset's fair market value.

Who Genmab A/S competes with

EXEL (exelixis.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple NUVL (Nuvalent)|Price-to-Revenue Multiple Kymera Therapeutics, Inc.|IDEAYA Bio - P/S Multiple|Price to Sales Enliven Corp|ORIC (ORIC Pharmaceuticals) - Market Cap to Revenue|RLAY: Market Cap to Sales Volume|NRIX (Nurix Therapeutics, Inc.) - P/S Multiple|Price to Sales Tyra Biosciences Inc TYRA|P/S Multiple VSTM|Monte Rosa Corp - Market Cap to Revenue Ratio|Cullinan Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IMRX|CCCC: Market Cap to Revenue|Black Diamond Therapeutics, Inc. - Market Cap to Sales Volume|RPTX: P/S Multiple|PMV Pharmaceuticals, Inc - Market Capitalization-to-Revenue Ratio|KPTI (Karyopharm Therapeutics, Inc.) - P/S Multiple|Price to Sales Propanc Biopharma, Inc. PPCB|Price-to-Revenue Ratio Bio Green Med Solution (BGMS)|AADI (aadibio.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALRN (Aileron Therapeutics, Inc.)|P/S Multiple Blueprint Medicines Corp. BPMC|GLYC - Price-to-Revenue Ratio|Price-to-Sales Ratio SWTX